IO Biotech receives InnoBooster grant
IO Biotech has received an InnoBooster grant from Innovation Fund Denmark to support the development of its in vivo checkpoint vaccine models
At present no preclinical in vivo models are available for the testing of vaccine based targeting of IDO. The aim of IO Biotech's InnoBooster project is to develop one or more translational in vivo models for the testing of an IDO checkpoint vaccine - both alone and in combination with other immune modulatory drugs.
- Innovation Fund Denmark invests in innovative ideas with the potential to create growth and jobs in Denmark. We are extremely proud to be considered and granted this investment, which will help us boost our research activities significantly, says CEO Mai-Britt Zocca.
For more information about InnoBooster click here.